HONG KONG – Japan could welcome nine biosimilar drugs to the market in the coming years, thanks to a commercialization deal between Amgen Inc. and local company Daiichi Sankyo Co. Ltd. The Thousand Oaks, Calif.-based pharma major said it inked a deal with Daiichi Sankyo to bring nine of its biosimilar drugs, some now undergoing late-stage clinical studies, to the Japanese market.
HONG KONG – A decade after the U.S. launch, Glaxosmithkline plc's (GSK) Cervarix vaccine to prevent the human papillomavirus (HPV) is in the home stretch to launch as the first HPV vaccine in Mainland China.
HONG KONG – Japan could welcome nine biosimilar drugs to the market in the coming years, thanks to a commercialization deal between Amgen Inc. and local company Daiichi Sankyo Co. Ltd. The Thousand Oaks, Calif.-based pharma major said it inked a deal with Daiichi Sankyo to bring nine of its biosimilar drugs, some now undergoing late-stage clinical studies, to the Japanese market.
HONG KONG – China's multibillion-dollar precision medicine initiative is shaping up with a nearly ¥642 million (US$96 million) investment for 61 key projects ready to go.
HONG KONG – China's multibillion-dollar precision medicine initiative is shaping up with a nearly ¥642 million (US$96 million) investment for 61 key projects ready to go.
HONG KONG – Increasingly concerned that the unchecked use of antibiotics is rapidly creating widespread resistance, regulators in Asia are developing stronger regulations and controls.
HONG KONG – Increasingly concerned that the unchecked use of antibiotics is rapidly creating widespread resistance, regulators in Asia are developing stronger regulations and controls.
HONG KONG – Stepped up regulations and a curb on the use of antibiotics is hurting the bottom line of antibiotic makers in China. And there is little chance of a change any time soon.
